Protara Therapeutics: End Of 2025 Proving Eventful Indeed
Protara Therapeutics (TARA) maintains strong momentum with TARA-002, showing durable, high complete response rates in NMIBC and promising efficacy in lymphatic malformations. TARA-002's 6-month complete response rate of 69% in BCG-naive NMIBC patients and 100% clinical success in lymphatic malformations reinforce its competitive positioning. With over two years of cash runway, TARA is well-capitalized to reach pivotal regulatory and clinical milestones, without near-term dilution risk.
Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript
Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript
Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript
Protara Therapeutics, Inc. ( TARA ) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations November 19, 2025 8:30 AM EST Company Participants Justine O'Malley - Senior Vice President of Investor Relations & Corporate Affairs Jesse Shefferman - Co-founder, CEO, President & Director Jacqueline Zummo - Co-Founder & Chief Scientific Operations Officer William Conkling - Chief Commercial Officer Conference Call Participants Jesse Jones Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Vishwesh Shah - TD Cowen, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and welcome to the Protara Update Call. We ask that you please hold all questions until the completion of the formal remarks at which time you will be given instructions for the question-and-answer session.
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
Protara Therapeutics (TARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
TARA's leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA's pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives.
Protara Therapeutics: Rising From The Ashes
Protara Therapeutics' TARA-002 showed promising Phase 2 results, significantly improving its valuation and offering a strong risk-reward setup despite recent stock fluctuations. The company raised $100M at $6.25 per share, ensuring a solid cash runway for potential Phase 3 trials and further development. Protara's current enterprise value is $70.2M, significantly undervalued compared to competitors like CG Oncology and Engene Holdings, indicating substantial upside potential.
Protara Therapeutics: Carving New Roads In Bladder Cancer
Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potentially extending to 3-4 years with a $100 million capital raise. Despite positive early data, the small patient sample size necessitates caution; larger trials are needed to confirm efficacy and safety.
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025.
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?
On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.
